The Cancer-HIV/AIDS Treatment Conundrum

The prostate cancer conundrum.

In 2003, the American Cancer Society estimates that 220 900 men will be diagnosed with prostate cancer and that 28 900 will die from this disease (1). Since the introduction of testing for prostate-specific antigen (PSA), the incidence of prostate cancer has increased, whereas the mortality from this disease has decreased. During the early 1990s, mortality from prostate cancer peaked in the Uni...

Cancer Conundrum

The main event is when physiologic EMT is seen in gastrulation; formation and migration of neural crest cells.[3] The progression of EMT is further classified into primary (1°), secondary (2°) and tertiary (3°) EMT,[2] depending on the number or sequential sweeps of EMT and mesenchymal‐epithelial transition (MET).[2] MET signifies the conversion of the mesenchymal phenotype back into the epithe...

The cancer conundrum.

Thirty-four patients with previously treated, advanced, low grade NHL were treated with Fludarabine, a deamination-resistant analogue of adenosine arabinoside, at a dose of 25 mg m-2 intravenously, daily for 5 days (median number of cycles= 3, range 1 -10). Complete remission (CR) was achieved in six and partial remission (PR) in a further seven. Overall, responses were seen in 11/23 patients (...

The antioxidant conundrum in cancer.

The health-related effects of interactions between reactive oxygen species (ROS) and dietary antioxidants and the consequences of dietary antioxidant supplementation on human health are by no means clear. Although ROS, normal byproducts of aerobic metabolism, are essential for various defense mechanisms in most cells, they can also cause oxidative damage to DNA, proteins, and lipids, resulting ...

THE CONUNDRUM OF EUTHANASIA